Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib - Concepedia

Concepedia

Publication | Open Access

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

DOI Full Paper Access

401

Citations

13

References

2019

Year

Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Afsheen N. Iqbal, Shirish M. Gadgeel, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann

Annals of Oncology

Clinical ImmunologyAutoimmune DiseaseImmunologyImmune Checkpoint InhibitorAutoimmunityPharmacotherapyImmunologic DiseaseImmunosuppressionImmunotherapyMedicineImmune DysregulationSequential Pd-

References

	Year	Citations

Page 1

Page 1